Farm the turd -- beat the herd
Followers | 88 |
Posts | 10,527 |
Boards Moderated | 4 |
Alias Born | 02/17/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$YOD - YOU On Demand Launches YOU Cinema Movie Service on Xiaomi OTT Set-Top Boxes
http://www.barchart.com/headlines/story/611199/you-on-demand-launches-you-cinema-movie-service-on-xiaomi-ott-set-top-boxes
$JASO tanking on downgrade...
$NTP (formerly NTE) reports Q1...interesting business shift & approval for new Gushu land development, but full permits and approval still 1 year out before phase 1 construction, and business is abysmal in the meantime.
http://en.prnasia.com/story/96582-0.shtml
$SVA - Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV)
Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease 04/28 03:09 AM
--------------------------------------------------------------------------------
BEIJING, April 28, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA:$6.00,00$0.07,001.18%) , a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries. According to the agreement, Sinovac has committed to commercializing the vaccine in China, inclusive of conducting clinical trials, obtaining regulatory approval, and launching the sIPV vaccine. In addition, Sinovac has committed to having the capacity to supply, or making arrangements for the supply of, sIPV to the public sector of other countries in sufficient quantities to make a meaningful contribution to meeting global demand (e.g. at least 20 million doses annually).
In developing countries around the globe including China, oral polio vaccine (OPV) is widely utilized to eradicate polio. OPV is a live attenuated formulation, which contains a weakened form of poliovirus. Although OPV is considered safe and effective, in extremely rare instances, the live attenuated vaccine virus in OPV can cause paralysis, resulting in cases of vaccine-associated paralytic polio (VAPP) or circulating vaccine-derived poliovirus (cVDPVs). Therefore, to eliminate the risk of such cases, OPV will be phased out from routine immunization programs around the world. To enable countries to maintain immunity levels, inactivated polio vaccines (IPV) will be introduced. Sabin IPV is both safer to manufacturer and more affordable as compared to the currently available Salk IPV. The global demand for IPV is increasing as the Global Polio Eradication Initiative has called for IPV to be introduced into 126 countries currently using OPV only by the end of 2015. According to Eradication and Endgame Strategic Plan developed under the Global Polio Eradication Initiative, from 2014 to 2018, the use of OPV in routine immunization will be gradually ceased.
The WHO called for Expressions of Interest (EOI) in 2010, 2011 and 2012 from private or public sector vaccine manufactures interested incollaborating with the WHO and Intravacc to develop and supply sIPV under the Global Polio Eradication Initiative. Sinovac submitted its EOI in 2012 and was selected as a technology transfer recipient after the qualification review and site inspection by the WHO and Intravacc.
National Health and Family Planning Commission of China is developing a vaccination strategy to add at least one dose of IPV into its national Expanded Program of Immunization (EPI). At present, no IPV is produced by manufacturers in China. Imported IPV became available in September 2009, but the supply is limited and the vaccine has to be paid for out-of-pocket by the recipient.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are honored to partner with WHO and Intravacc to develop and commercialize sIPV for future distribution both domestically and internationally. As part of selection process, we demonstrated our fully integrated vaccine capabilities, inclusive of conducting clinical trials, obtaining regulatory approval and operating GMP certified manufacturing facilities, and exemplified our commercialization expertise based on our broad vaccine portfolio."
Mr. Yin continued, "Polio represents a significant unmet medical need in China and other developing countries. By moving forward with the clinical development of sIPV with the objective of producing this vaccine in China, Sinovac is helping keep China polio-free and achieve a lasting polio-free world, free of all polio paralytic cases."
Ms. Gisella Frijlink, Chief Executive Officer of Intravacc, stated, "We are pleased to enter into the collaboration with Sinovac, one of the leading Chinese vaccine companies. This project will enable Sinovac to supply a safe and affordable sIPV vaccine to the Chinese population, as well as to other countries. It also exemplifies the leading position of the Netherlands in the vaccine field and Intravacc's important role in the global eradication of polio."
$NVIV InVivo Therapeutics Initiates First Clinical Trial of Neuro-Spinal Scaffold
Scaffold Designed to Facilitate Neural Growth in Spinal Cord Injury 04/28 05:00 AM
--------------------------------------------------------------------------------
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV:$1.924,0$0.424,028.27%) announced today that it has begun shipment of its innovative investigational device, a degradable polymer Neuro-Spinal Scaffold for spinal cord injury (SCI) patients, for initiation of the company’s first clinical trial. InVivo has pioneered a new treatment platform utilizing a biocompatible polymer-based device that is intended to promote structural support for spinal cord regeneration while improving functional recovery and prognosis after a traumatic SCI. In preclinical studies, the Neuro-Spinal Scaffold promoted cell adhesion, neurite sprouting, the growth of remodeled spinal cord tissue containing myelinated axons, and improved motor function. There currently is no effective treatment for paralysis caused by SCI. The company estimates the worldwide market for treating acute complete SCI to be over $500 million annually, and the chronic SCI market to be over $10 billion. This is the first in-human trial of InVivo’s novel investigational device, a critical step in addressing a major unmet need for patients with SCI.
This first clinical study, which is approved by the FDA, is a pilot trial to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. The Company then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).
The initial clinical site, The University of Arizona Medical Center in Tucson, AZ, has received Institutional Review Board (IRB) approval and has executed all necessary contracts with InVivo. Surgical training will occur upon receipt of the Neuro-Spinal Scaffold, allowing the site to then begin subject enrollment. Ali A. Baaj, MD, Assistant Professor of Surgery and Director of the Spinal Neurosurgery Program at The University of Arizona Medical Center, is the Principal Investigator. In commenting about the significance of this trial, Dr. Baaj said: “Spinal cord injury research is a priority for us at the University of Arizona Spinal Neurosurgery program. We are excited to collaborate with InVivo Therapeutics (NVIV:$1.924,0$0.424,028.27%) on this groundbreaking clinical trial as we strive to help patients who are affected by this devastating condition.”
InVivo has received IRB approval from two additional sites and expects these two sites to be open for enrollment in the second quarter. “The InVivo team has put forth a tremendous effort to bring this innovative product to the clinic,” InVivo CEO Mark Perrin said. “I anticipate continued momentum as additional sites are initiated in this important study. We are dedicated to patients whose lives have been forever changed by their traumatic injury. InVivo’s Neuro-Spinal Scaffold technology may again change their lives …
$CCM - Concord Medical's China Growth Plans
http://www.forbes.com/sites/benjaminshobert/2014/04/23/concord-medicals-china-growth-plans/?partner=yahootix
Watchlist: $LAS $MCOX $SPU $SVA $THTI $ZA $CLWT $JRJC $HPJ $DHRM $DATE $CTC $CHLN $CCM
http://finviz.com/quote.ashx?t=LAS,MCOX,SPU,SVA,THTI,ZA,CLWT,JRJC,HPJ,DHRM,DATE,CTC,CHLN,CCM&ty=c&ta=1&p=d
Brilliant speech by Stefan Molyneux on bitcoin and war
$CHLN some serious insider buying here
http://archive.fast-edgar.com/20140423/A3A2F22CZM22J2ZA222W2MZB2S7ECB22Z262
http://archive.fast-edgar.com/20140423/ALAZ722CZM2272ZA22252MZA2TNKZB22ZQ62
Hmmm numbers can't be good can they? Need news or at least a juicy update in the earnings pr to get this turn a movin'
E's posted in April so no NT..I'm back in for a few. Last shot for the company to do something with that cash. Tutes have already bailed and retail patience wearing thin....
Interesting, thanks. That alleviates my concerns of an NT hitting.
Nice, thanks
$CMGE psar trigger, momo stock, will get the lovin as spec money flowing
ZA _ seems likely the won't report on time. Still sticking by my prediction they go dark.
SEC Charges a Former Biopharmaceutical Company Executive and Two Others with Insider Trading
http://www.sec.gov/servlet/Satellite/News/PressRelease/Detail/PressRelease/1370541541673
$CXDC very strong...this likely set it off http://www.twitlonger.com/show/n_1s1e7ok
$VIMC Vimicro International Signs Agreement on SVAC-Compliant Chips with the First Research Institute of the Ministry of Public Security http://en.prnasia.com/story/96241-0.shtml
$VIMC Vimicro International Signs Agreement on SVAC-Compliant Chips with the First Research Institute of the Ministry of Public Security http://en.prnasia.com/story/96241-0.shtml
$AUTCF AutoChina International Reports 2013 Fourth Quarter and Year-End Financial Results, a 138% Increase in Commercial Vehicle Revenues in 2013 04/21 05:30 AM
--------------------------------------------------------------------------------
SHIJIAZHUANG, CHINA -- (Marketwired) -- 04/21/14 -- AutoChina International Limited (AUTCF:$8.00,00$-4.15,00-34.16%) ("AutoChina" or the "Company") , China's largest commercial vehicle sales, servicing, leasing, and support network, today reported financial results for the fourth quarter and year ended December 31, 2013.
Operational Highlights
4,290 commercial vehicles leased in fourth quarter of 2013, a 425.7% increase from 816 in prior-year period
11,902 commercial vehicles leased in 2013, a 121.0% increase from 5,385 in 2012
During the 2013 fourth quarter, the Company established eight additional commercial vehicle financing and service centers. As of December 31, 2013, AutoChina (AUTCF:$8.00,00$-4.15,00-34.16%) operated 546 financing and service centers in 26 provinces.
Company announces development of two new products: 1) KyPay, a new form of electronic payment that offers its members a line of credit, and 2) TopAuto Net, a cloud-based e-commerce platform enabling transportation and logistics businesses in China to manage their operations online
Q4 2013 Financial Highlights (comparisons are year over year)
Total revenues of $238.3 million, up 359.0% from $51.9 million, largely due to the increase in new commercial vehicle leases initiated during Q4 2013
Gross profit of $22.5 million, up 31.1% from $17.2 million
Net income of $3.8 million, or $0.16 per diluted share, compared to $2.6 million, or $0.11 per diluted share
Adjusted EBITDA of $11.3 million, a 65.6% increase from $6.8 million
Full-year 2013 Financial Highlights (comparisons are year over year)
Total revenues of $658.1 million, up 97.6% from $333.1 million, largely due to the increase in new commercial vehicle leases initiated during 2013
Gross profit of $73.5 million, compared to $88.8 million, primarily as a result of the significantly larger number of new trucks purchased for leases initiated during 2013, which have relatively low margin, while finance income, which is relatively high margin, contributed a greater percentage of revenue in 2012
Net income of $11.8 million, or $0.50 per diluted share, compared to $23.5 million, or $0.99 per diluted share
Adjusted EBITDA of $33.8 million, compared to $50.3 million
Operational and Market Review
$CHDX Chindex Signs Amended Merger Agreement with TPG and Fosun Pharma -- Increases Consideration from $19.50 to $24.00 per Share in Cash and Implied Equity Value from $369 Million to $461 Million http://en.prnasia.com/story/96238-0.shtml
$PWRD $GAME Perfect World Entered Into Agreements to Acquire Shares in Shanda Games http://en.prnasia.com/story/96231-0.shtml
Yup out now from 2.36 but want back in.
$ATV 20F fwiw..its ugly http://archive.fast-edgar.com/20140417/A32VNQ2DZZ2RNZZU229N2ZXK6JQHZZ22Z262
GALT popzilla, oversold and bouncing off the 200 day on news
http://finance.yahoo.com/news/galectin-therapeutics-announces-first-patient-141911409.html
$GALT - Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis 04/17 07:19 AM
--------------------------------------------------------------------------------
NORCROSS, Ga., April 17, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (GALT:$10.26,00$-0.02,00-0.19%) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration (FDA) for this Phase 1 clinical trial. The second cohort follows highly successful results from the first cohort showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02 treatment resulted in significant improvement in multiple biomarkers of fibrosis and liver inflammation in patients with NASH with advanced fibrosis (see full results: http://galectintherapeutics.com/wp-content/uploads/2014/03/20140401GT020FirstCohortFINAL.pdf). The remaining patients in cohort 2 are expected to be enrolled over the next few weeks and we anticipate reporting the results of cohort 2 around the end of July.
"We were extremely pleased with the results of the first cohort, which demonstrated significant biomarker effects on fibrosis and inflammation in all the patients treated with GR-MD-02, coupled with good safety and tolerability," said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. (GALT:$10.26,00$-0.02,00-0.19%) "These positive results have propelled the enrollment of the second cohort with strong participation across our clinical trial sites. We anticipate the cohort 2 results will further support the use of GR-MD-02 in patients with NASH and advanced fibrosis, with the goal of reversing fibrosis and preventing complications of cirrhosis and liver transplantation."
The trial is titled "A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis." Trial design details can be found at http://clinicaltrials.gov/ct2/show/NCT01899859?term=gt-020&rank=1. In 2013, Galectin Therapeutics (GALT:$10.26,00$-0.02,00-0.19%) received Fast Track designation from the FDA for this clinical development program. FDA grants Fast Track designation to help expedite review and approval of drugs in development that treat serious or life threatening diseases and fill an unmet medical need.
About Fatty Liver Disease with Advanced Fibrosis
Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to affect nine to 15 million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis.
About Galectin Therapeutics (GALT:$10.26,00$-0.02,00-0.19%)
Galectin Therapeutics (GALT:$10.26,00$-0.02,00-0.19%) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
$CHLN chair of audit committee resigns http://archive.fast-edgar.com/20140417/A2AJ622CZM22W2Z2222U2CZGPVNTZB22X262
ZOOM - gotta be quick on news, get in get out. No reason to trade until then imo.
$WB and $LEJU IPO today
$ZX - Q4/FY2013 results http://en.prnasia.com/story/96139-0.shtml
$LAS - Lentuo Launches Pre-owned Car Quality Certification Program 04/17 12:52 AM
--------------------------------------------------------------------------------
BEIJING, April 17, 2014 /PRNewswire/ -- Lentuo International Inc. (LAS:$3.39,00$0.14,004.31%) , a leading non-state-owned automobile retailer headquartered in Beijing, today announced it has launched a quality certification program to support its growing Certified pre-owned car business and improve confidence and transparency in the pre-owned car industry.
Effective today all of the Company's mid- to high-end pre-owned cars will receive a complete technical inspection and analysis to ensure they have no significant frame or internal damage, are in excellent working order and meet or exceed generally accepted standards for a particular make and model. Only those cars that successfully pass this inspection will be offered for sale. This will provide much needed price transparency, increase buyer confidence and make financial institutions more comfortable in financing purchases and managing credit risk.
These cars, labeled Lentuo Certified Quality will be sold through the O2O platform announced by the Company on March 3, 2014, which will incorporate the Company's flagship showroom in Beijing and additional pre-owned dealerships to be opened as the Company expands geographically.
Lentuo (LAS:$3.39,00$0.14,004.31%) expects various substantial synergistic effects resulting from the build–up of this dedicated pre-owned car business. Among others, revenues from repair and maintenance should expand as the Company will offer discounts to buyers of its certified pre-owned cars.
Financing for pre-owned cars in China has been constrained by the lack of pricing transparency and quality standards, somewhat slowing down the expansion of this much needed market. With its reputation for quality, advanced technological equipment and the launch of this rigorous certification program, Lentuo (LAS:$3.39,00$0.14,004.31%) has gained the strategic support of China Orient Tiantong Capital Management Ltd., a subsidiary of China Orient Asset Management Corp, a major state-owned financial asset management company. China Orient Tiantong will leverage its institutional power and substantial funding capabilities to help Lentuo (LAS:$3.39,00$0.14,004.31%) provide adequate financing to the certified pre-owned car buyers.
"With the launch of this program, the O2O platform, and the strategic financial support of China Orient Tiantong, we now have in place the key elements necessary to build a robust pre-owned car business that we expect to grow beyond Beijing over time," said Lentuo (LAS:$3.39,00$0.14,004.31%) founder and chairman, Mr. Hetong Guo.
Mr. Guo continued: "Our program, with its certified expert inspection and industry-leading warranties, will help, we believe, to greatly increase the level of confidence in our pre-owned cars and make the pricing of these cars far more transparent. This should help us drive our sales of pre-owned cars to a higher level, especially once the O2O platform is operational. We also expect additional benefits as a result of the synergistic effect with our after-sale services."
http://en.prnasia.com/story/96132-0.shtml
$CREG China Recycling Energy Corporation Appoints Christensen as Strategic Investor Relations Advisor 04/16 07:27 AM
--------------------------------------------------------------------------------
XI'AN, China, April 16, 2014 /PRNewswire-FirstCall/ -- China Recycling Energy Corp. (CREG:$2.95,00$0.00,000.00%) , a leading industrial waste-to-energy solution provider in China, today announced the appointment of Christensen, a global IR and financial media communications firm, as its investor relations advisor.
Mr. Ku Guohua, Chairman and Chief Executive Officer of CREG, stated, "We are pleased to engage Christensen as our strategic advisor. Their extended capital markets expertise and considerable experience working with large scale energy companies matches our needs well. Christensen is a highly professional firm that has had a growing presence in China for more than 12 years and has acquired in-depth understanding of Chinese business culture and Chinese geo-political issues through its work with dozens of state-owned and private companies. We strongly believe that Christensen's international reach, global professional team, and ability to work closely with its clients will help us strengthen our communication with the capital markets."
Mr. Rene Vanguestaine, Chairman and Chief Executive Officer of Christensen, commented, "We strongly believe that CREG has substantial growth opportunities arising from the size of its addressable market and the Chinese government's support for energy-saving and environmental protection industry. We are excited at the prospect of helping investors better understand the value of its business model and its potential for greater shareholder value."
About China Recycling Energy Corp. (CREG:$2.95,00$0.00,000.00%)
$STV here's the official pr http://en.prnasia.com/story/96092-0.shtml
$DHRM - Dehaier Acquired Multiple International Players' Authorization for Chinese Government Procurement 04/16 05:30 AM
--------------------------------------------------------------------------------
BEIJING, April 16, 2014 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (DHRM:$6.17,00$-0.58,00-8.59%) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and sleep respiratory products in China, today announced that it will serve as the exclusive product-appointed distribution agent for some of the world's leading medical equipment companies in bidding for multiple government procurement projects in China, the procurement projects we are bidding for are designated by these companies.
The appointed products the company is authorized for the procurement include Harmonic System from Johnson & Johnson Medical (Shanghai) Ltd., the MasterScreen™ pulmonary function testing system from CareFusion (Shanghai) Commercial and Trading Co. Ltd., ventilator from Weinmann GmbH + Co. KG, infusion pump from B. Braun Medical (Shanghai) International Trading Co., Ltd., spectrophotometer from Shimadzu (China) Co., Ltd. and portable color Doppler ultrasound, versatile anesthesia machine and multi-parameter monitor from Mindray Medical International Limited. The aggregate value of the procurement projects is expected to be approximately $21 million.
Dehaier Chairman and CEO Mr. Ping Chen stated, "With rich experience and resources in the Chinese medical equipment industry, especially with its mature sales and distribution networks across China, Dehaier has earned a strong reputation and increased product support from global medical equipment companies who seek to penetrate the vast Chinese healthcare market. Today we are excited and honored to enter into these exclusive arrangements with international medical equipment manufacturers to distribute their flagship products in China and to participate in potential government procurement projects. In the past year, the Chinese government procurement business has been one of Dehaier's major focuses. With a fast growing economy and aging population, we believe the Chinese government will continue to invest more to upgrade its healthcare system, particularly China's medical equipment. By partnering with world-renowned medical device companies, we are confident that our government procurement business will progress in 2014 and beyond. Dehaier is currently working on a preparation for the procurement biddings and expects to win them in quarters to come."
$HERB - Yasheng Group Joint Venture With Natural Capital Investment Ltd
https://www.menafn.com/d26d4e7e-49b6-470c-817b-f4c45f1e4ca3/Yasheng-Group-Joint-Venture-With-Natural-Capital-Investment-Ltd?src=main